- Home
- IAC vs OGN Comparison
IAC vs OGN Comparison
Compare IAC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAC
- OGN
- Stock Information
- Founded
- IAC N/A
- OGN 1923
- Country
- IAC United States
- OGN United States
- Employees
- IAC N/A
- OGN N/A
- Industry
- IAC Computer Software: Programming Data Processing
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- IAC Technology
- OGN Health Care
- Exchange
- IAC Nasdaq
- OGN Nasdaq
- Market Cap
- IAC 4.5B
- OGN 4.0B
- IPO Year
- IAC 1992
- OGN N/A
- Fundamental
- Price
- IAC $42.27
- OGN $15.89
- Analyst Decision
- IAC Buy
- OGN Hold
- Analyst Count
- IAC 13
- OGN 3
- Target Price
- IAC $67.92
- OGN $21.33
- AVG Volume (30 Days)
- IAC 812.3K
- OGN 4.3M
- Earning Date
- IAC 02-11-2025
- OGN 02-13-2025
- Dividend Yield
- IAC N/A
- OGN 7.06%
- EPS Growth
- IAC N/A
- OGN 120.97
- EPS
- IAC N/A
- OGN 5.04
- Revenue
- IAC $3,875,960,000.00
- OGN $6,409,000,000.00
- Revenue This Year
- IAC N/A
- OGN $3.29
- Revenue Next Year
- IAC N/A
- OGN $1.93
- P/E Ratio
- IAC N/A
- OGN $3.15
- Revenue Growth
- IAC N/A
- OGN 4.21
- 52 Week Low
- IAC $39.61
- OGN $13.87
- 52 Week High
- IAC $58.29
- OGN $23.10
- Technical
- Relative Strength Index (RSI)
- IAC 40.96
- OGN 55.80
- Support Level
- IAC $39.61
- OGN $15.52
- Resistance Level
- IAC $43.70
- OGN $16.23
- Average True Range (ATR)
- IAC 1.29
- OGN 0.53
- MACD
- IAC 0.22
- OGN 0.10
- Stochastic Oscillator
- IAC 54.62
- OGN 79.22
About IAC IAC Inc.
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
About OGN Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.